Effect of baseline body mass index on glycemic control and weight change with exenatide monotherapy in Chinese drug-naïve type 2 diabetic patients.
BACKGROUND
The weight-reducing effect of exenatide has been proved, but too much weight loss in normal-weight patients may concern physicians. This study evaluated the effects of exenatide monotherapy on glycemic control and weight change in normal-weight, overweight, and obese patients with newly diagnosed type 2 diabetes (T2D).


METHODS
In this multicenter prospective study, 29 normal-weight, 54 overweight, and 27 obese newly diagnosed and drug-naïve patients with T2D were treated with exenatide for 48 weeks. The primary efficacy endpoint was the effect of baseline body mass index (BMI) on glycemic control, measured as the change in HbA1c from baseline to Week 48 compared among different BMI groups. Other endpoints included comparisons of the effects of exenatide on fasting plasma glucose (FPG), postprandial plasma glucose (PPG), body weight, and other metabolic indices.


RESULTS
After 48-week treatment, the estimated mean changes in HbA1c in normal-weight, overweight, and obese patients were -1.9%, -1.8%, and -1.5%, respectively (P = 0.290 among groups after adjustment for baseline values). There were similar declines in FPG and 0.5- and 2-hour PPG among groups. There were non-significant trends from normal-weight to overweight to obese patients for increased weight reduction (decreases of 2.2, 3.9, and 4.0 kg, respectively; P = 0.104) and changes in waist circumference (decreases of 2.2, 3.2, and 5.6 cm, respectively; P = 0.078).


CONCLUSIONS
Baseline BMI had no effect on glycemic control, weight change, or other metabolic indices with exenatide monotherapy. Normal-weight patients with T2D would benefit from exenatide as much as overweight or obese patients on glucose control, without increased risk of excess weight loss.
['Deng|Hongrong|H|', 'Lin|Shuo|S|', 'Yang|Xubin|X|', 'Lv|Jing|J|', 'Luo|Sihui|S|', 'Zeng|Longyi|L|', 'Weng|Jianping|J|', 'Xu|Wen|W|', '|||']
D015415:Biomarkers D001786:Blood Glucose D015992:Body Mass Index D001835:Body Weight D016022:Case-Control Studies D003924:Diabetes Mellitus, Type 2 D000077270:Exenatide D005260:Female D005500:Follow-Up Studies D006442:Glycated Hemoglobin A D006801:Humans D007004:Hypoglycemic Agents D008297:Male D008875:Middle Aged D009765:Obesity D050177:Overweight D011379:Prognosis D011446:Prospective Studies
exenatide type 2 diabetes body weight 2型糖尿病 体重 艾塞那肽